McKesson Reports Fiscal 2020 Third Quarter Results

Third Quarter Highlights, Year-over-Year:

  • Consolidated revenues of $59.2 billion, reflecting 5% growth.
  • Earnings per diluted share decreased 56% to $1.06.
  • Adjusted Earnings per diluted share of $3.81, an increase of 12%.

Fiscal 2020 Guidance:

  • Reaffirmed fiscal 2020 Adjusted Earnings per diluted share guidance range of $14.60 to $14.80; previously raised from $14.00 to $14.60 on January 13, 2020.

IRVING, Texas–(BUSINESS WIRE)–McKesson Corporation (NYSE:MCK) today reported results for the third quarter ended December 31, 2019.

Fiscal 2020 Third-Quarter and Year-to-Date Result Summary

 

 

Third Quarter

 

Year-to-Date

($ in millions, except per share amounts)

 

FY20

 

FY19

 

Change

 

FY20

 

FY19

 

Change

Revenues

 

$

59,172

 

$

56,208

 

        5

 

 %

$

172,516

 

 

$

161,890

 

7

 

 %

Income / (loss)from continuing operations1

 

191

 

470

 

(59

)

 

 

(109

)

 

829

 

(113

)

 

Adjusted Earnings1,2

 

685

 

664

 

3

 

 

 

1,971

 

 

1,967

 

 

 

Earnings / (loss) per diluted share1

 

1.06

 

2.41

 

(56

)

 

 

(0.60

)

 

4.17

 

(114

)

 

Adjusted Earnings per diluted share1,2  

 

3.81

 

3.40

 

12

 

 

 

10.71

 

 

9.89

 

8

 

 

1Reflects continuing operations attributable to McKesson, net of tax

2Represents a non-GAAP financial measure; refer to the reconciliations of non-GAAP financial measures included in accompanying schedules

“We delivered solid operating performance and we are pleased to report third-quarter adjusted earnings results ahead of our expectations,” said Brian Tyler, chief executive officer. “McKesson’s unwavering focus on strategic and operational execution is demonstrated in the adjusted operating profit growth we reported in the third quarter across our core operating segments. Additionally, we have deployed meaningful capital toward share repurchases year-to-date, delivering further value to our shareholders. Our outlook for fiscal 2020 Adjusted EPS remains unchanged from the prior guidance we provided on January 13th, 2020.”

Third-quarter revenues were $59.2 billion, up 5% from a year ago. On an FX-adjusted basis, revenues grew 6%, primarily driven by growth in the U.S. Pharmaceutical and Specialty Solutions segment, largely due to branded pharmaceutical price increases and higher volumes from retail national account customers.

Third-quarter earnings per diluted share of $1.06 included a pre- and post-tax charge of $282 million within our European Pharmaceutical Solutions segment for the remeasurement to fair value of assets and liabilities held for sale related to the expected formation of a new German wholesale joint venture with Walgreens Boots Alliance.

Third-quarter Adjusted Earnings per diluted share was $3.81 compared to $3.40 a year ago, an increase of 12%, primarily driven by growth in the U.S. Pharmaceutical and Specialty Solutions, Medical Surgical and European segments and a lower share count, partially offset by the previously anticipated increase in corporate expenses and a higher tax rate. Prior year third-quarter results included a pre-tax charge of $60 million related to a customer bankruptcy, partially offset by a $17 million pre-tax reversal of an accrued estimated liability related to the New York State Opioid Stewardship Act. Excluding the impact of these prior year items from Adjusted Earnings, third-quarter adjusted results per diluted share increased approximately 7% year-over-year.

For the first nine months of the fiscal year, McKesson returned $2.2 billion of cash to shareholders via $1.9 billion of common stock repurchases and $222 million of dividend payments. During the first nine months of the fiscal year, McKesson used cash from operations of $280 million, and invested $338 million internally, resulting in negative free cash flow of $618 million.

U.S. Pharmaceutical and Specialty Solutions Segment

  • Third-quarter revenues were $46.9 billion, up 6%, driven primarily by branded pharmaceutical price increases and higher volumes from retail national account customers, partially offset by branded to generic conversions.
  • Third-quarter operating profit was $687 million and operating margin was 1.46%. Adjusted operating profit was $658 million, up 11% from a year ago. Prior year third-quarter results included a $60 million pre-tax charge related to a customer bankruptcy, partially offset by a $17 million pre-tax reversal of an accrued estimated liability related to the New York State Opioid Stewardship Act. Excluding the net $43 million impact of these prior year items, adjusted operating profit increased approximately 3%, driven by continued growth in the specialty businesses. Adjusted operating margin was 1.40%, up 6 basis points.

European Pharmaceutical Solutions Segment

  • Third-quarter revenues were $6.9 billion, flat on a reported basis and up 3% on an FX-adjusted basis, driven primarily by growth in the pharmaceutical distribution business.
  • Third-quarter operating loss was ($303 million) and operating margin was (4.37)%, primarily driven by a pre- and post-tax charge of $282 million for the remeasurement to fair value of assets and liabilities held for sale related to the expected formation of a new German wholesale joint venture with Walgreens Boots Alliance. Adjusted operating profit was $80 million, up 16%, and adjusted operating margin was 1.15%. On an FX-adjusted basis, adjusted operating profit was $82 million, up 19%, and adjusted operating margin was 1.16%, up 16 basis points, driven in part by expense rationalization. 

Medical-Surgical Solutions Segment

  • Third-quarter revenues were $2.1 billion, up 6%, driven primarily by growth in the Primary Care business, largely due to higher pharmaceutical volumes and an early start to influenza season.
  • Third-quarter operating profit was $124 million and operating margin was 5.79%. Adjusted operating profit was $184 million, up 8%, and adjusted operating margin was 8.59%, up 14 basis points. The year-over-year increase primarily reflects organic growth in the Primary Care business.

Other remaining businesses

  • Third-quarter revenues were $3.2 billion, up 6% on a reported basis and up 5% on an FX-adjusted basis, primarily driven by growth in the Canadian business.
  • Third-quarter operating profit was $61 million. Adjusted operating profit was $214 million, down 4% on both a reported and FX-adjusted basis, as increased investment spend within the MRxTS business was partially offset by growth in the Canadian business.

Company Updates

  • On February 4, 2020, McKesson’s wholly-owned subsidiary, PF2 SpinCo, Inc., filed a registration statement with the Securities and Exchange Commission (SEC) relating to a potential exit of the company from its investment in the Change Healthcare joint venture.
  • McKesson was selected by the Department of Veterans Affairs to continue to serve as the prime pharmaceutical provider when the current contract expires in August 2020.
  • On December 12, 2019, McKesson and Walgreens Boots Alliance announced an agreement to create a joint venture that is expected to combine their respective pharmaceutical wholesale businesses in Germany.
  • For the seventh year in a row, McKesson was honored as one of the “Best Places to Work for LGBTQ Equality” by the Human Rights Campaign (HRC) Foundation, achieving 100 percent on the HRC’s 2020 Corporate Equality Index (CEI).
  • McKesson appointed Nancy Flores as Executive Vice President, Chief Information and Technology Officer effective January 13, 2020, following Kathy McElligott’s announced retirement.

Fiscal 2020 Outlook

  • McKesson reaffirmed fiscal 2020 Adjusted Earnings per diluted share guidance range of $14.60 to $14.80, which was previously narrowed and raised from $14.00 to $14.60 on January 13, 2020.

Conference Call Details

The company has scheduled a conference call for today, Tuesday, February 4th at 8:00 AM ET to discuss the company’s financial results. A live audio webcast of the conference call will be available on McKesson’s Investor Relations website at http://investor.mckesson.com. The conference call can also be accessed by dialing 786-815-8297. The password is ‘McKesson’. A telephonic replay of this conference call will be available for 14 calendar days. For individuals wishing to listen to the replay, the dial-in number is 404-537-3406 and the pass code is 6206708. An archive of the conference call will also be available on the company’s Investor Relations website at http://investor.mckesson.com.

Non-GAAP Financial Measures

GAAP refers to the U.S. generally accepted accounting principles. This press release includes GAAP financial measures as well as Non-GAAP financial measures, including Adjusted Earnings, FX-Adjusted results and Free Cash Flow which are financial measures not calculated in accordance with GAAP. Refer to the “Supplemental Non-GAAP Financial Information” section of the accompanying financial statement tables for the definitions and usefulness of the Company’s Non-GAAP financial measures and the attached schedules for reconciliations of the differences between the Non-GAAP financial measures and their most directly comparable GAAP financial measures.

The company does not provide forward-looking guidance on a GAAP basis as McKesson is unable to provide a quantitative reconciliation of this forward-looking non-GAAP measure to the most directly comparable forward-looking GAAP measure, without unreasonable effort, because McKesson cannot reliably forecast LIFO inventory-related adjustments, gains from antitrust legal settlements, restructuring, impairment and related charges, and other adjustments, which are difficult to predict and estimate. These items are inherently uncertain and depend on various factors, many of which are beyond the company’s control, and as such, any associated estimate and its impact on GAAP performance could vary materially.

Cautionary Statements

Except for historical information contained in this press release, matters discussed may constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, that involve risks and uncertainties that could cause actual results to differ materially from those in those statements. It is not possible to identify all such risks and uncertainties. The reader should not place undue reliance on forward-looking statements, such as references to the expected joint venture in Germany, which speak only as of the date they are first made. Except to the extent required by law, the company undertakes no obligation to publicly update forward-looking statements. Forward-looking statements may be identified by their use of terminology such as “believes”, “expects”, “anticipates”, “may”, “will”, “should”, “seeks”, “approximately”, “intends”, “plans”, “estimates” or the negative of these words or other comparable terminology. The discussion of financial trends, strategy, plans, assumptions or intentions may also include forward-looking statements. We encourage investors to read the important risk factors described in the company’s Form 10-K, Form 10-Q and Form 8-K reports filed with the Securities and Exchange Commission. These risk factors include, but are not limited to: changes in the healthcare industry and regulatory environment; fluctuations in foreign currency exchange rates; the impact of the Change Healthcare joint venture on the company’s results of operations; the company’s ability to manage and complete divestitures and distributions; material adverse resolution of pending legal proceedings, including those related to the distribution of controlled substances; cyberattack, natural disaster, or malfunction of sophisticated internal computer systems to perform as designed; and the potential inadequacy of insurance to cover property loss or liability claims.

About McKesson Corporation

McKesson Corporation is a global leader in healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology. McKesson partners with pharmaceutical manufacturers, providers, pharmacies, governments and other organizations in healthcare to help provide the right medicines, medical products and healthcare services to the right patients at the right time, safely and cost-effectively. United by our ICARE shared principles, our employees work every day to innovate and deliver opportunities that make our customers and partners more successful — all for the better health of patients. McKesson has been named the “Most Admired Company” in the healthcare wholesaler category by FORTUNE, a “Best Place to Work” by the Human Rights Campaign Foundation, and a top military-friendly company by Military Friendly. For more information, visit www.mckesson.com.

Schedule 1

McKESSON CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS – GAAP

(unaudited)

(in millions, except per share amounts)

 

 

Three Months Ended December 31,

 

 

 

 

Nine Months Ended December 31,

 

 

 

2019

 

2018

 

Change

 

2019

 

2018

 

Change

Revenues

$

59,172

 

 

$

56,208

 

 

5

 

%

 

$

172,516

 

 

$

161,890

 

 

7

 

%

Cost of Sales

(56,139

)

 

(53,238

)

 

5

 

 

 

(163,829

)

 

(153,337

)

 

7

 

 

Gross Profit

3,033

 

 

2,970

 

 

2

 

 

 

8,687

 

 

8,553

 

 

2

 

 

Operating Expenses (1) (2) (3)

(2,535

)

 

(2,156

)

 

18

 

 

 

(6,861

)

 

(6,219

)

 

10

 

 

Goodwill Impairment Charges (4)

(2

)

 

(21

)

 

(90

)

 

 

(2

)

 

(591

)

 

(100

)

 

Restructuring, Impairment and Related Charges (5)

(136

)

 

(110

)

 

24

 

 

 

(204

)

 

(288

)

 

(29

)

 

Total Operating Expenses

(2,673

)

 

(2,287

)

 

17

 

 

 

(7,067

)

 

(7,098

)

 

 

 

Operating Income

360

 

 

683

 

 

(47

)

 

 

1,620

 

 

1,455

 

 

11

 

 

Other Income (Expense), Net (6) (7)

26

 

 

84

 

 

(69

)

 

 

(15

)

 

144

 

 

(110

)

 

Equity Earnings and Charges from Investment in Change Healthcare Joint Venture (8) (9) (10)

(28

)

 

(50

)

 

(44

)

 

 

(1,478

)

 

(162

)

 

812

 

 

Interest Expense

(64

)

 

(67

)

 

(4

)

 

 

(184

)

 

(194

)

 

(5

)

 

Income (Loss) from Continuing Operations Before Income Taxes

294

 

 

650

 

 

(55

)

 

 

(57

)

 

1,243

 

 

(105

)

 

Income Tax Benefit (Expense) (11)

(47

)

 

(123

)

 

(62

)

 

 

111

 

 

(245

)

 

(145

)

 

Income from Continuing Operations

247

 

 

527

 

 

(53

)

 

 

54

 

 

998

 

 

(95

)

 

Income (Loss) from Discontinued Operations, Net of Tax

(5

)

 

(1

)

 

400

 

 

 

(12

)

 

1

 

 

NM

 

Net Income

242

 

 

526

 

 

(54

)

 

 

42

 

 

999

 

 

(96

)

 

Net Income Attributable to Noncontrolling Interests

(56

)

 

(57

)

 

(2

)

 

 

(163

)

 

(169

)

 

(4

)

 

Net Income (Loss) Attributable to McKesson Corporation

$

186

 

 

$

469

 

 

(60

)

%

 

$

(121

)

 

$

830

 

 

(115

)

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnings (Loss) Per Common Share Attributable to McKesson Corporation (a)

 

 

 

 

 

 

 

 

 

 

 

 

 

Diluted (b)

 

 

 

 

 

 

 

 

 

 

 

 

 

Continuing operations

$

1.06

 

 

$

2.41

 

 

(56

)

%

 

$

(0.60

)

 

$

4.17

 

 

(114

)

%

Discontinued operations

(0.03

)

 

(0.01

)

 

200

 

 

 

(0.06

)

 

0.01

 

 

(700

)

 

Total

$

1.03

 

 

$

2.40

 

 

(57

)

%

 

$

(0.66

)

 

$

4.18

 

 

(116

)

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

 

 

 

 

 

 

 

 

 

 

 

Continuing operations

$

1.06

 

 

$

2.42

 

 

(56

)

%

 

$

(0.60

)

 

$

4.19

 

 

(114

)

%

Discontinued operations

(0.02

)

 

(0.01

)

 

100

 

 

 

(0.06

)

 

 

 

NM

 

 

Total

$

1.04

 

 

$

2.41

 

 

(57

)

%

 

$

(0.66

)

 

$

4.19

 

 

(116

)

%

Dividends Declared per Common Share

$

0.41

 

 

$

0.39

 

 

 

 

 

$

1.21

 

 

$

1.12

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted Average Common Shares

 

 

 

 

 

 

 

 

 

 

 

 

 

Diluted

180

 

 

195

 

 

(8

)

%

 

183

 

 

199

 

 

(8

)

%

Basic

179

 

 

194

 

 

(8

)

 

 

183

 

 

198

 

 

(8

)

 

(a)

Certain computations may reflect rounding adjustments.

(b)

Net loss per diluted share for the nine months ended December 31, 2019 is calculated by excluding dilutive securities from the denominator due to their antidilutive effects.

NM Computation not meaningful

Refer to the section entitled “Financial Statement Notes” of this release.

For additional disclosures, refer to our applicable filings with the SEC, including our Quarterly Reports on Form 10-Q for fiscal 2020 and 2019 as well as our Annual Report on Form 10-K for fiscal 2019.

Schedule 2A

McKESSON CORPORATION

RECONCILIATION OF GAAP OPERATING RESULTS TO ADJUSTED EARNINGS (NON-GAAP)

(unaudited)

(in millions, except per share amounts)

 

 

Three Months Ended December 31, 2019

 

Change Vs. Prior Quarter

 

As Reported (GAAP)

Amortization of Acquisition- Related Intangibles

Transaction- Related Expenses and Adjustments

LIFO Inventory- Related Adjustments

Gains from Antitrust Legal Settlements

Restructuring, Impairment and Related Charges, Net

Other Adjustments, Net

Adjusted Earnings (Non-GAAP)

 

As Reported (GAAP)

Adjusted Earnings (Non-GAAP)

Gross Profit

$

3,033

 

$

 

$

 

$

(66

)

$

(22

)

$

 

$

 

$

2,945

 

 

2

%

4

%

Total Operating Expenses (3) (5)

$

(2,673

)

$

113

 

$

324

 

$

 

$

 

$

136

 

$

23

 

$

(2,077

)

 

17

%

3

%

Other Income, Net

$

26

 

$

1

 

$

2

 

$

 

$

 

$

 

$

10

 

$

39

 

 

(69

)%

39

%

Equity Earnings and Charges from Investment in Change Healthcare Joint Venture (10)

$

(28

)

$

63

 

$

15

 

$

 

$

 

$

 

$

1

 

$

51

 

 

(44

)%

(2

)%

Income from Continuing Operations Before Income Taxes

$

294

 

$

177

 

$

341

 

$

(66

)

$

(22

)

$

136

 

$

34

 

$

894

 

 

(55

)%

5

%

Income Tax Expense (11)

$

(47

)

$

(43

)

$

(34

)

$

17

 

$

6

 

$

(21

)

$

(31

)

$

(153

)

 

(62

)%

18

%

Income from Continuing Operations, Net of Tax, Attributable to McKesson Corporation (a)

$

191

 

$

134

 

$

307

 

$

(49

)

$

(16

)

$

115

 

$

3

 

$

685

 

 

(59

)%

3

%

Earnings per Diluted Common Share from Continuing Operations, Net of Tax, Attributable to McKesson Corporation (b)

$

1.06

 

$

0.75

 

$

1.71

 

$

(0.27

)

$

(0.09

)

$

0.64

 

$

0.01

 

$

3.81

 

(c)

(56

)%

12

%

Diluted Weighted Average Common Shares

180

 

180

 

180

 

180

 

180

 

180

 

180

 

180

 

 

(8

)%

(8

)%

 

 

Three Months Ended December 31, 2018

 

 

As Reported (GAAP)

Amortization of Acquisition-

Related Intangibles

Transaction- Related Expenses and Adjustments

LIFO Inventory- Related Adjustments

Gains from Antitrust Legal Settlements

Restructuring, Impairment and Related Charges, Net

Other Adjustments, Net

Adjusted Earnings (Non-GAAP)

 

Gross Profit

$

2,970

 

$

 

$

 

$

(21

)

$

(104

)

$

 

$

 

$

2,845

 

 

Total Operating Expenses (5)

$

(2,287

)

$

122

 

$

27

 

$

 

$

 

$

110

 

$

21

 

$

(2,007

)

 

Other Income, Net (7)

$

84

 

$

 

$

 

$

 

$

 

$

 

$

(56

)

$

28

 

 

Equity Earnings and Charges from Investment in Change Healthcare Joint Venture (10)

$

(50

)

$

75

 

$

25

 

$

 

$

 

$

 

$

2

 

$

52

 

 

Income from Continuing Operations Before Income Taxes

$

650

 

$

197

 

$

52

 

$

(21

)

$

(104

)

$

110

 

$

(33

)

$

851

 

 

Income Tax Expense (11)

$

(123

)

$

(50

)

$

(13

)

$

6

 

$

27

 

$

(18

)

$

41

 

$

(130

)

 

Income from Continuing Operations, Net of Tax, Attributable to McKesson Corporation (a)

$

470

 

$

147

 

$

39

 

$

(15

)

$

(77

)

$

92

 

$

8

 

$

664

 

 

Earnings per Diluted Common Share from Continuing Operations, Net of Tax, Attributable to McKesson Corporation (b)

$

2.41

 

$

0.76

 

$

0.20

 

$

(0.08

)

$

(0.39

)

$

0.47

 

$

0.03

 

$

3.40

 

 

Diluted Weighted Average Common Shares

195

 

195

 

195

 

195

 

195

 

195

 

195

 

195

 

 

(a)

Calculated as “Net Income (Loss) Attributable to McKesson Corporation” less “Income (Loss) from Discontinued Operations, Net of Tax” as presented in the Condensed Consolidated Statements of Operations – GAAP.

(b)

Certain computations may reflect rounding adjustments.

(c)

Adjusted Earnings per diluted share on an FX-Adjusted basis for the third quarter of fiscal 2020 was $3.82, which excludes the foreign currency exchange effect of $0.01.

Refer to the section entitled “Financial Statement Notes” of this release.

For more information relating to the Adjusted Earnings (Non-GAAP) and FX-Adjusted (Non-GAAP) definitions, refer to the section entitled “Supplemental Non-GAAP Financial Information” of this release.

Schedule 2B

McKESSON CORPORATION

RECONCILIATION OF GAAP OPERATING RESULTS TO ADJUSTED EARNINGS (NON-GAAP)

(unaudited)

(in millions, except per share amounts)

 

 

Nine Months Ended December 31, 2019

 

Change Vs. Prior Period

 

As Reported (GAAP)

Amortization of Acquisition- Related Intangibles

Transaction- Related Expenses and Adjustments

LIFO Inventory- Related Adjustments

Gains from Antitrust Legal Settlements

Restructuring, Impairment and Related Charges, Net

Other Adjustments, Net

Adjusted Earnings (Non-GAAP)

 

As Reported (GAAP)

Adjusted Earnings (Non-GAAP)

Gross Profit

$

8,687

 

$

 

$

 

$

(114

)

$

(22

)

$

(5

)

$

 

$

8,546

 

 

2

%

2

%

Total Operating Expenses (2) (3) (5)

$

(7,067

)

$

343

 

$

357

 

$

 

$

 

$

204

 

$

109

 

$

(6,054

)

 

%

3

%

Other Income (Expense), Net (6)

$

(15

)

$

1

 

$

5

 

$

 

$

 

$

 

$

133

 

$

124

 

 

(110

)%

39

%

Equity Earnings and Charges from Investment in Change Healthcare Joint Venture (8) (9) (10)

$

(1,478

)

$

203

 

$

305

 

$

 

$

 

$

 

$

1,168

 

$

198

 

 

812

%

15

%

Income (Loss) from Continuing Operations Before Income Taxes

$

(57

)

$

547

 

$

667

 

$

(114

)

$

(22

)

$

199

 

$

1,410

 

$

2,630

 

 

(105

)%

3

%

Income Tax Benefit (Expense) (11)

$

111

 

$

(130

)

$

(117

)

$

29

 

$

6

 

$

(36

)

$

(359

)

$

(496

)

 

(145

)%

16

%

Income (Loss) from Continuing Operations, Net of Tax, Attributable to McKesson Corporation (a)

$

(109

)

$

417

 

$

550

 

$

(85

)

$

(16

)

$

163

 

$

1,051

 

$

1,971

 

 

(113

)%

%

Earnings (Loss) Per Diluted Common Share from Continuing Operations, Net of Tax, Attributable to McKesson Corporation (b) (c)

$

(0.60

)

$

2.27

 

$

2.99

 

$

(0.46

)

$

(0.09

)

$

0.89

 

$

5.72

 

$

10.71

 

(d)

(114

)%

8

%

Diluted Weighted Average Common Shares

183

 

184

 

184

 

184

 

184

 

184

 

184

 

184

 

 

(8

)%

(8

)%

 

 

Nine Months Ended December 31, 2018

 

 

As Reported (GAAP)

Amortization of Acquisition- Related Intangibles

Transaction- Related Expenses and Adjustments

LIFO Inventory- Related Adjustments

Gains from Antitrust Legal Settlements

Restructuring, Impairment and Related Charges, Net

Other Adjustments, Net

Adjusted Earnings (Non-GAAP)

 

Gross Profit

$

8,553

 

$

 

$

1

 

$

(64

)

$

(139

)

$

 

$

 

$

8,351

 

 

Total Operating Expenses (1) (4) (5)

$

(7,098

)

$

364

 

$

84

 

$

 

$

 

$

288

 

$

508

 

$

(5,854

)

 

Other Income, Net (7)

$

144

 

$

1

 

$

 

$

 

$

 

$

 

$

(56

)

$

89

 

 

Equity Earnings and Charges from Investment in Change Healthcare Joint Venture (10)

$

(162

)

$

229

 

$

99

 

$

 

$

 

$

 

$

6

 

$

172

 

 

Income from Continuing Operations Before Income Taxes

$

1,243

 

$

594

 

$

184

 

$

(64

)

$

(139

)

$

288

 

$

458

 

$

2,564

 

 

Income Tax Expense (11)

$

(245

)

$

(148

)

$

(46

)

$

17

 

$

36

 

$

(44

)

$

2

 

$

(428

)

 

Income from Continuing Operations, Net of Tax, Attributable to McKesson Corporation (a)

$

829

 

$

446

 

$

138

 

$

(47

)

$

(103

)

$

244

 

$

460

 

$

1,967

 

 

Earnings Per Diluted Common Share from Continuing Operations, Net of Tax, Attributable to McKesson Corporation (b)

$

4.17

 

$

2.24

 

$

0.69

 

$

(0.24

)

$

(0.52

)

$

1.23

 

$

2.32

 

$

9.89

 

 

Diluted Weighted Average Common Shares

199

 

199

 

199

 

199

 

199

 

199

 

199

 

199

 

 

(a)

Calculated as “Net Income (Loss) Attributable to McKesson Corporation” less “Income (Loss) from Discontinued Operations, Net of Tax” as presented in the Condensed Consolidated Statements of Operations – GAAP.

(b)

Certain computations may reflect rounding adjustments.

(c)

We calculate GAAP net loss per diluted share for the nine months ended December 31, 2019 using a weighted average of 183 million common shares, which excludes dilutive securities from the denominator due to their antidilutive effect when calculating a net loss per diluted share. We calculate Adjusted Earnings per diluted share (Non-GAAP) for the nine months ended December 31, 2019 on a fully diluted basis, using a weighted average of 184 million common shares. Because we show the GAAP to Non-GAAP per share reconciling items on a fully diluted basis, any cross-footing differences in those items are due to different weighted average share counts.

(d)

Adjusted Earnings per diluted share on an FX-Adjusted basis for fiscal 2020 was $10.74, which excludes the foreign currency exchange effect of $0.03.

Refer to the section entitled “Financial Statement Notes” of this release.

For more information relating to the Adjusted Earnings (Non-GAAP) and FX-Adjusted (Non-GAAP) definitions, refer to the section entitled “Supplemental Non-GAAP Financial Information” of this release.

Schedule 3A

McKESSON CORPORATION
RECONCILIATION OF GAAP SEGMENT OPERATING RESULTS TO ADJUSTED EARNINGS (NON-GAAP)
(unaudited)
(in millions)

 

Three Months Ended December 31,

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2019

 

2018

 

GAAP

 

Non-GAAP

 

Change

As Reported (GAAP)

 

Adjustments

 

Adjusted Earnings (Non-GAAP)

 

As Reported (GAAP)

 

Adjustments

 

Adjusted Earnings (Non-GAAP)

 

Foreign Currency Effects

 

FX-Adjusted

 

Foreign Currency Effects

 

FX-Adjusted

 

As Reported (GAAP)

 

Adjusted Earnings (Non-GAAP)

 

FX-Adjusted (GAAP)

 

FX-Adjusted (Non-GAAP)

REVENUES
U.S. Pharmaceutical and Specialty Solutions

$

46,923

$

$

46,923

$

44,279

$

$

44,279

$

$

46,923

$

$

46,923

6

%

6

%

6

%

6

%

European Pharmaceutical Solutions

6,931

6,931

6,911

6,911

168

7,099

168

7,099

3

3

Medical-Surgical Solutions

2,141

2,141

2,012

2,012

2,141

2,141

6

6

6

6

Other (a)

3,177

3,177

3,006

3,006

(7

)

3,170

(7

)

3,170

6

6

5

5

Revenues

$

59,172

$

$

59,172

$

56,208

$

$

56,208

$

161

$

59,333

$

161

$

59,333

5

%

5

%

6

%

6

%

 
OPERATING PROFIT (5)
U.S. Pharmaceutical and Specialty Solutions

$

687

$

(29

)

$

658

$

671

$

(78

)

$

593

$

$

687

$

$

658

2

%

11

%

2

%

11

%

European Pharmaceutical Solutions (3)

(303

)

383

80

26

43

69

(3

)

(306

)

2

82

NM

16

NM

19

Medical-Surgical Solutions

124

60

184

136

34

170

124

184

(9

)

8

(9

)

8

Other (a) (7) (10)

61

153

214

74

150

224

2

63

1

215

(18

)

(4

)

(15

)

(4

)

Operating Profit

569

567

1,136

907

149

1,056

(1

)

568

3

1,139

(37

)

8

(37

)

8

Corporate

(211

)

33

(178

)

(190

)

52

(138

)

(1

)

(212

)

(178

)

11

29

12

29

Income from Continuing Operations Before Interest Expense and Income Taxes

$

358

$

600

$

958

$

717

$

201

$

918

$

(2

)

$

356

$

3

$

961

(50

)%

4

%

(50

)%

5

%

 
OPERATING PROFIT AS A % OF REVENUES
U.S. Pharmaceutical and Specialty Solutions

1.46

%

1.40

%

1.52

%

1.34

%

1.46

%

1.40

%

(6

)bp

 

6

bp

 

(6

)bp

 

6

bp

 

European Pharmaceutical Solutions

(4.37

)

1.15

0.38

1.00

(4.31

)

1.16

(475

)

15

(469

)

16

Medical-Surgical Solutions

5.79

8.59

6.76

8.45

5.79

8.59

(97

)

14

(97

)

14

Contacts

Holly Weiss, 972-969-9174 (Investors)

Holly.Weiss@McKesson.com
David Matthews, 214-952-0833 (Media)

David.Matthews@McKesson.com

Read full story here

error: Content is protected !!